| Literature DB >> 31870830 |
Yalda Rahbar Saadat1, Bahram Niknafs2, Seyed Mahdi Hosseiniyan Khatibi2, Mohammadreza Ardalan2, Hasan Majdi3, Zahra Bahmanpoor4, Sima Abediazar2, Sepideh Zununi Vahed5.
Abstract
Hyperphosphatemia is a mineral bone-disease that increases cardiovascular complications and all-cause mortality in chronic kidney disease (CKD) patients. Oral phosphate binders absorb the dietary phosphate to prevent its high plasma levels. Moreover, they can adsorb some uremic toxins and decrease inflammation. A few recent studies highlight an ignored effect of phosphate binders on gut microbiota. Phosphorous is a major nutrient for survival and reproduction of bacteria and its intestinal concentration may impact the activity and composition of the gut microbiota. CKD is a state of an altered gut microbiome and bacterial-derived uremic toxins stimulate cardiovascular disease and systemic inflammation. The identification of the impact of phosphate binders on gut opens a new era in nephrology and fill the existing gap in interpretation of beneficial effects of phosphate binders. This review aims to highlight the impact of oral phosphate binders on the gut microbiome in CKD.Entities:
Keywords: Chronic kidney disease; ESRD; Hemodialysis; Hyperphosphatemia; Microbiome; Phosphorus; Uremic toxins
Mesh:
Substances:
Year: 2019 PMID: 31870830 DOI: 10.1016/j.ejphar.2019.172892
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432